Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Not Confirmed
Not Confirmed
26-28 May, 2026
Not Confirmed
Not Confirmed
27-28 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Industry Trade Show
Not Confirmed
26-28 May, 2026
Industry Trade Show
Not Confirmed
27-28 May, 2026
Digital content
NEWS #PharmaBuzz
29 Jan 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/formation-bio-licenses-mir-124-activator-for-autoimmune-diseases-from-ctfh-302673553.html
10 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-and-formation-bio-enter-exclusive-development-and-licensing-agreement-for-lnk01006-302637950.html
18 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/formation-bio-expands-leadership-team-with-top-biotech-and-pharma-executives-to-accelerate-ai-driven-drug-development-302560861.html
29 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/formation-bio-licenses-first-in-class-anti-cd226-autoimmune-program-from-imidomics-302515217.html
24 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jaksyk-inhibitor-to-sanofi-302487403.html
09 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/formation-bio-announces-first-class-of-entrepreneurs-in-residence-to-drive-pipeline-growth-and-strategic-partnerships-302476651.html
Drugs in Development
Details:
BLKR201 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Lead Product(s): BLKR201
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 30, 2026
Lead Product(s) : BLKR201
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of BLKR201 in Healthy Adult Participants
Details : BLKR201 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2026
Details:
Through the licensing deal for FHND5032, targeting miR-124, the agreement aims to advance treatment options for autoimmune diseases.
Lead Product(s): FHND5032
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Recipient: Jiangsu Chia Tai Feng Hai Pharmaceutical
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 29, 2026
Lead Product(s) : FHND5032
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Jiangsu Chia Tai Feng Hai Pharmaceutical
Deal Size : $500.0 million
Deal Type : Licensing Agreement
Formation Bio Licenses miR-124 Activator for Autoimmune Diseases from CTFH
Details : Through the licensing deal for FHND5032, targeting miR-124, the agreement aims to advance treatment options for autoimmune diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 29, 2026
Details:
Through the acquisition of LNK01006, a small molecule product, the deal aims to advance the targeting of TYK2.
Lead Product(s): LNK01006
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Recipient: Lynk Pharmaceuticals
Deal Size: $605.0 million Upfront Cash: $605.0 million
Deal Type: Acquisition December 10, 2025
Lead Product(s) : LNK01006
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Recipient : Lynk Pharmaceuticals
Deal Size : $605.0 million
Deal Type : Acquisition
Lynk Pharmaceuticals, Formation Bio Sign Deal for LNK01006
Details : Through the acquisition of LNK01006, a small molecule product, the deal aims to advance the targeting of TYK2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $605.0 million
December 10, 2025
Details:
Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study.
Lead Product(s): Gusacitinib
Therapeutic Area: Undisclosed Brand Name: ASN-002
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Sanofi
Deal Size: $627.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 23, 2025
Lead Product(s) : Gusacitinib
Therapeutic Area : Undisclosed
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $627.6 million
Deal Type : Licensing Agreement
Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor
Details : Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi. Sanofi will explore its potential in a new indication not previously studied through a phase 1 study.
Product Name : ASN-002
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 23, 2025
Details:
The fund aims to advance the pipeline, which includes the company lead product ASN008, a sodium channel blocker. Currently, it is being evaluated for the treatment of atopic dermatitis.
Lead Product(s): ASN008
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Sanofi
Deal Size: $372.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 26, 2024
Lead Product(s) : ASN008
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $372.0 million
Deal Type : Series D Financing
Formation Bio Raises Series D to Expand Drug Pipeline and AI-Driven Development Platform
Details : The fund aims to advance the pipeline, which includes the company lead product ASN008, a sodium channel blocker. Currently, it is being evaluated for the treatment of atopic dermatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 26, 2024
Details:
AVID200 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Primary Myelofibrosis.
Lead Product(s): AVID200
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Sponsor: John Mascarenhas
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2019
MPN-RC 118 AVID200 in Myelofibrosis
Details : AVID200 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2019
Details:
AVID200 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): AVID200
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Protein
Recipient: Bristol Myers Squibb
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 08, 2019
Lead Product(s) : AVID200
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancie...
Details : AVID200 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 08, 2019
Details:
AVID100 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): AVID100
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2017
Lead Product(s) : AVID100
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AVID100 in Advanced Epithelial Carcinomas
Details : AVID100 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 29, 2017
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
